The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat

Brain Research

Volumn 959, Issue 2, 2003, Pages 243-250

  Melani, Alessia ^a   Pantoni, Leonardo ^a   Bordoni, Francesca ^a   Gianfriddo, Marco ^a   Bianchi, Loria ^a   Vannucchi, Maria Giuliana ^a   Bertorelli, Rosalia ^b   Monopoli, Angela ^b,c   Pedata, Felicita ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Schering Plough Research Institute   (Italy)

^c NicOx Research Institue   (Italy)

Author keywords

Adenosine A2A receptor; Amino acid; Cerebral ischemia, focal; Motor behavior; Rat

Indexed keywords

4 AMINOBUTYRIC ACID; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE; ASPARTIC ACID; GLUTAMIC ACID; TAURINE; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN ISCHEMIA; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DRUG EFFECT; LOCOMOTION; MALE; MICRODIALYSIS; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORY DYSFUNCTION; WAKEFULNESS; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; SECRETION; WISTAR RAT;

ANIMALS; BRAIN ISCHEMIA; CORPUS STRIATUM; MALE; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; PYRIMIDINES; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; TRIAZOLES;

EID: 0037427516     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03753-8     Document Type: Article

References (53)

1. Bianchi L., Della C.L., Tipton K.F. Simultaneous determination of basal and evoked output levels of aspartate, glutamate, taurine and 4-aminobutyric acid during microdialysis and from superfused brain slices. J. Chromatogr. B Biomed. Sci. Appl. 723:1999;47-59.
2. Bona E., Aden U., Gilland E., Fredholm B.B., Hagberg H. Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology. 36:1997;1327-1338.
3. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19:1999;9192-9200.
4. Choi D.W., Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13:1990;171-182.
5. 2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport. 11:2000;2591-2595.
6. Dionisotti S., Zocchi C., Varani K., Borea P.A., Ongini E. Effects of adenosine derivatives on human and rabbit platelet aggregation. Correlation of adenosine receptor affinities and antiaggregatory activity. Naunyn Schmiedebergs Arch. Pharmacol. 346:1992;673-676.
7. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22:1999;391-397.
8. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol. 118:1996;1461-1468.
9. 2A-receptors. Glia. 18:1996;152-160.
10. Flavin M.P., Ho L.T. Propentofylline protects neurons in culture from death triggered by macrophage or microglial secretory products. J. Neurosci. Res. 56:1999;54-59.
11. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., Williams M. Nomenclature and classification of purinoceptors. Pharmacol. Rev. 46:1994;143-156.
12. 2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci. 55:1994;L61-L65.
13. Garcia J.H., Liu K.F., Ho K.L. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex. Stroke. 26:1995;636-642.
14. Garcia J.H., Wagner S., Liu K.F., Hu X.J. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke. 26:1995;627-634.
15. Gebicke-Haerter P.J., Van Calker D., Norenberg W., Illes P. Molecular mechanisms of microglial activation. A. Implications for regeneration and neurodegenerative diseases. Neurochem. Int. 29:1996;1-12.
16. Giovannini M.G., Bartolini L., Kopf S.R., Pepeu G. Acetylcholine release from the frontal cortex during exploratory activity. Brain Res. 784:1998;218-227.
17. Heiss W.D., Hayakawa T., Waltz A.G. Cortical neuronal function during ischemia. Effects of occlusion of one middle cerebral artery on single-unit activity in cats. Arch. Neurol. 33:1976;813-820.
18. Hillered L., Hallstrom A., Segersvard S., Persson L., Ungerstedt U. Dynamics of extracellular metabolites in the striatum after middle cerebral artery occlusion in the rat monitored by intracerebral microdialysis. J. Cereb. Blood Flow Metab. 9:1989;607-616.
19. Hunter A.J., Hatcher J., Virley D., Nelson P., Irving E., Hadingham S.J., Parsons A.A. Functional assessments in mice and rats after focal stroke. Neuropharmacology. 39:2000;806-816.
20. 2A receptor antagonist. Brain Res. 800:1998;328-335.
21. 2A receptor agonists and antagonists. Neuroscience. 85:1998;229-237.
22. Latini S., Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J. Neurochem. 79:2001;463-484.
23. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:1989;84-91.
24. Lyden P.D., Lonzo L.M., Nunez S.Y., Dockstader T., Mathieu-Costello O., Zivin J.A. Effect of ischemic cerebral volume changes on behavior. Behav. Brain Res. 87:1997;59-67.
25. Matsumoto K., Graf R., Rosner G., Shimada N., Heiss W.D. Flow thresholds for extracellular purine catabolite elevation in cat focal ischemia. Brain Res. 579:1992;309-314.
26. Melani A., Pantoni L., Corsi C., Bianchi L., Monopoli A., Bertorelli R., Pepeu G., Pedata F. Striatal outflow of adenosine, excitatory amino acids, gamma-aminobutyric acid, and taurine in awake freely moving rats after middle cerebral artery occlusion: correlations with neurological deficit and histopathological damage. Stroke. 30:1999;2448-2454.
27. 2A adenosine receptor antagonist, SCH 58261, in the rat. J. Pharmacol. Exp. Ther. 285:1998;9-15.
28. 2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport. 9:1998;3955-3959.
29. Nagasawa H., Kogure K. Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion. Stroke. 20:1989;1037-1043.
30. Oja S.S., Saransaari P. Taurine as osmoregulator and neuromodulator in the brain. Metab. Brain Dis. 11:1996;153-164.
31. Olive M.F., Mehmert K.K., Hodge C.W. Modulation of extracellular neurotransmitter levels in the nucleus accumbens by a taurine uptake inhibitor. Eur. J. Pharmacol. 409:2000;291-294.
32. Ossowska K. Interaction between striatal excitatory amino acid and gamma-aminobutyric acid (GABA) receptors in the turning behaviour of rats. Neurosci. Lett. 202:1995;57-60.
33. Ozyurt E., Graham D.I., Woodruff G.N., McCulloch J. Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia in the cat. J. Cereb. Blood Flow Metab. 8:1988;138-143.
34. Park C.K., Nehls D.G., Graham D.I., Teasdale G.M., McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann. Neurol. 24:1988;543-551.
35. Paxinos G., Watson G. The Rat Brain in Stereotaxic Coordinates. 1982;Academic Press, New York.
36. 2A receptors in ischemia. Ann. NY Acad. Sci. 939:2001;74-84.
37. 2A adenosine receptors leads to c-fos inhibition in a rat model of brain ischemia. Pharmacol. Res. 45:2002;125-128.
38. Phillis J.W., Smith-Barbour M., O'Regan M.H., Perkins L.M. Amino acid and purine release in rat brain following temporary middle cerebral artery occlusion. Neurochem. Res. 19:1994;1125-1130.
39. 1 agonists in dopamine-denervated rats. Eur. J. Neurosci. 8:1996;1176-1181.
40. +-evoked glutamate release in the striatum. Eur. J. Pharmacol. 421:2001;177-180.
41. 2A receptor blockade prevents EEG and motor abnormalities in a rat model of Huntington's disease. Drug Dev. Res. 50:2000;69.
42. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmacol. 287:1995;215-217.
43. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22:2002;1967-1975.
44. Rabuffetti M., Sciorati C., Tarozzo G., Clementi E., Manfredi A.A., Beltramo M. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J. Neurosci. 20:2000;4398-4404.
45. 2A receptor agonist CGS 21680. Drug Dev. Res. 39:1996;108-114.
46. Simpson R.E., O'Regan M.H., Perkins L.M., Phillis J.W. Excitatory transmitter amino acid release from the ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists. J. Neurochem. 58:1992;1683-1690.
47. A receptors. Science. 269:1995;977-981.
48. 2B purinoceptor are coupled to production of nitric oxide in the regulation of blood pressure. Environ. Toxicol. Pharmacol. 2:1996;327-329.
49. 2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience. 79:1997;753-764.
50. Takagi K., Ginsberg M.D., Globus M.Y., Dietrich W.D., Martinez E., Kraydieh S., Busto R. Changes in amino acid neurotransmitters and cerebral blood flow in the ischemic penumbral region following middle cerebral artery occlusion in the rat: correlation with histopathology. J. Cereb. Blood Flow Metab. 13:1993;575-585.
51. 2A adenosine receptor antagonist. J. Pharmacol. Exp. Ther. 276:1996;398-404.
52. von Lubitz D.K. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 365:1999;9-25.
53. 2A receptor agonist and antagonist. Eur. J. Pharmacol. 287:1995;295-302.